These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 32071061)

  • 21. Prevalence of etravirine resistance associated mutations in HIV-1 strains isolated from infected individuals failing efavirenz: comparison between subtype B and non-B genetic variants.
    Pereira-Vaz J; Duque V; Pereira B; Mota V; Morais C; Saraiva-da-Cunha J; Meliço-Silvestre A
    J Med Virol; 2012 Apr; 84(4):551-4. PubMed ID: 22337292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana.
    Diphoko T; Gaseitsiwe S; Kasvosve I; Moyo S; Okatch H; Musonda R; Wainberg M; Makhema J; Marlink R; Novitsky V; Essex M
    AIDS Res Hum Retroviruses; 2018 Aug; 34(8):667-671. PubMed ID: 29732907
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of the virological response to etravirine in clinical practice: Comparison of three genotype algorithms.
    Cotte L; Trabaud MA; Tardy JC; Brochier C; Gilibert RP; Miailhes P; Trépo C; André P
    J Med Virol; 2009 Apr; 81(4):672-7. PubMed ID: 19235860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of discrepancies in the interpretation of antiretroviral drug resistance results in HIV-1 infected patients of Basque Country, Spain.
    Muñoz M; Carmona R; Pérez-Alvarez L; Cilla G; Suarez MD; Delgado E; Contreras G; Corral J; de Goicoetxea MJ; Medrano L; Lezaún MJ; Nájera R;
    J Clin Virol; 2005 Jul; 33(3):224-9. PubMed ID: 15911444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors.
    Varghese V; Shahriar R; Rhee SY; Liu T; Simen BB; Egholm M; Hanczaruk B; Blake LA; Gharizadeh B; Babrzadeh F; Bachmann MH; Fessel WJ; Shafer RW
    J Acquir Immune Defic Syndr; 2009 Nov; 52(3):309-15. PubMed ID: 19734799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predicted susceptibility of etravirine in HIV patients experiencing virological failure secondary to non-nucleoside reverse transcriptase inhibitor resistance in Argentina.
    Córdova E; Loiza E; Porteiro N; Mingrone H
    Enferm Infecc Microbiol Clin; 2011; 29(6):428-31. PubMed ID: 21592625
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine.
    Xu HT; Colby-Germinario SP; Asahchop EL; Oliveira M; McCallum M; Schader SM; Han Y; Quan Y; Sarafianos SG; Wainberg MA
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3100-9. PubMed ID: 23612196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
    Sterrantino G; Borghi V; Callegaro AP; Bruzzone B; Saladini F; Maggiolo F; Maffongelli G; Andreoni M; De Gennaro M; Gianotti N; Bagnarelli P; Vergori A; Antinori A; Zazzi M; Zaccarelli M;
    Int J Antimicrob Agents; 2019 Apr; 53(4):515-519. PubMed ID: 30769200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Resistance profile of rilpivirine].
    Imaz A; García F; di Yacovo S; Llibre JM
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():36-43. PubMed ID: 24252532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Etravirine: genetic barrier and resistance development].
    Llibre JM; Santos JR; Clotet B
    Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():32-9. PubMed ID: 20116626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short communication prevalence of susceptibility to etravirine by genotype and phenotype in samples received for routine HIV type 1 resistance testing in the United States.
    Picchio G; Vingerhoets J; Tambuyzer L; Coakley E; Haddad M; Witek J
    AIDS Res Hum Retroviruses; 2011 Dec; 27(12):1271-5. PubMed ID: 21557669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Switch from etravirine twice daily to once daily in non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-infected patients with suppressed viremia: the Monetra study.
    Schneider L; Ktorza N; Fourati S; Assoumou L; Courbon E; Caby F; Blanc C; Tindel M; Agher R; Marcelin AG; Calvez V; Peytavin G; Katlama C
    HIV Clin Trials; 2012; 13(5):284-8. PubMed ID: 23134629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS).
    Scherrer AU; Hasse B; von Wyl V; Yerly S; Böni J; Bürgisser P; Klimkait T; Bucher HC; Ledergerber B; Günthard HF
    HIV Med; 2009 Nov; 10(10):647-56. PubMed ID: 19732174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of etravirine (ETR)-RAMs at NNRTI failure and predictors of resistance to ETR in a large Italian resistance database (ARCA).
    Rusconi S; Adorni F; Bruzzone B; Di Biagio A; Meini G; Callegaro A; Punzi G; Boeri E; Pecorari M; Monno L; Gianotti N; Butini L; Galli L; Polilli E; Galli M;
    Clin Microbiol Infect; 2013 Oct; 19(10):E443-6. PubMed ID: 23621421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study.
    Lam EP; Moore CL; Gotuzzo E; Nwizu C; Kamarulzaman A; Chetchotisakd P; van Wyk J; Teppler H; Kumarasamy N; Molina JM; Emery S; Cooper DA; Boyd MA
    AIDS Res Hum Retroviruses; 2016 Sep; 32(9):841-50. PubMed ID: 27346600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues.
    Poveda E; de Mendoza C; Pattery T; González Mdel M; Villacian J; Soriano V
    AIDS; 2008 Nov; 22(17):2395-8. PubMed ID: 18981781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
    PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selection of nonnucleoside reverse transcriptase inhibitor-associated mutations in HIV-1 subtype C: evidence of etravirine cross-resistance.
    Neogi U; Shet A; Shamsundar R; Ekstrand ML
    AIDS; 2011 May; 25(8):1123-6. PubMed ID: 21505320
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.
    van Zyl GU; van der Merwe L; Claassen M; Zeier M; Preiser W
    J Med Virol; 2011 Oct; 83(10):1764-9. PubMed ID: 21837793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short communication: activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naive patients and week 48 pooled DUET study data.
    Vingerhoets J; Azijn H; Tambuyzer L; Dierynck I; De Meyer S; Rimsky L; Nijs S; De Smedt G; de Béthune MP; Picchio G
    AIDS Res Hum Retroviruses; 2010 Jun; 26(6):621-4. PubMed ID: 20507207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.